Fragment screening of infectious disease targets in a structural genomics environment

Methods in Enzymology

Volumn 493, Issue , 2011, Pages 533-556

  Begley, Darren W ^a,c   Davies, Douglas R ^a,c   C Hartley, Robert ^a,c   Edwards, Thomas E ^a,c   Staker, Bart L ^a,c   Van Voorhis, Wesley C ^b,c   Myler, Peter J ^c   Stewart, Lance J ^a,c  

^a Emerald BioStructures   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APO PROTEIN; ARGININE; BACTERIAL PROTEIN; GUANOSINE DIPHOSPHATE; LEAD; ORNITHINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENOME; BURKHOLDERIA PSEUDOMALLEI; CRYOPROTECTION; CRYSTAL STRUCTURE; CRYSTALLIZATION; GENE POOL; INFECTION; LIGAND BINDING; MOLECULAR LIBRARY; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; STRUCTURAL GENOMICS; X RAY CRYSTALLOGRAPHY;

EID: 79952371236     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381274-2.00021-2     Document Type: Chapter

References (107)

1. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guideposts for drug discovery Drug Discov. Today 10 2005 464 469
2. B.J. Akerley, E.J. Rubin, V.L. Novick, K. Amaya, N. Judson, and J.J. Mekalanos A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae Proc. Natl. Acad. Sci. USA 99 2002 966 971 (Pubitemid 34106619)
3. S.F. Altschul, W. Gish, W. Miller, E.W. Myers, and D.J. Lipman Basic local alignment search tool J. Mol. Biol. 215 1990 403 410
4. P.R. Andrews, D.J. Craik, and J.L. Martin Functional group contributions to drug-receptor interactions J. Med. Chem. 27 1984 1648 1657 (Pubitemid 15177908)
5. F.M. Assadi-Porter, M. Tonelli, E. Maillet, K. Hallenga, O. Benard, M. Max, and J.L. Markley Direct NMR detection of the binding of functional ligands to the human sweet receptor, a heterodimeric family 3 GPCR J. Am. Chem. Soc. 130 2008 7212 7213 (Pubitemid 351813199)
6. Begley, D. W., Hartley, R. C., Davies, D. R., Edwards, T. E., Leonard, J. T., Abendroth, J., Burris, C. A., Bhandari, J., Myler, P. J., and Stewart, L. J. Leveraging Structure Determination with Fragment Screening for Infectious Disease Drug Targets. J. Struct. Funct. Genomics. (manuscript in preparation)
7. S.D. Bembenek, B.A. Tounge, and C.H. Reynolds Ligand efficiency and fragment-based drug discovery Drug Discov. Today 14 2009 278 283
8. G.W. Bemis, and M.A. Murcko The properties of known drugs. 1. Molecular frameworks J. Med. Chem. 39 1996 2887 2893 (Pubitemid 26251026)
9. T.A. Binkowski, and A. Joachimiak Protein functional surfaces: Global shape matching and local spatial alignments of ligand binding sites BMC Struct. Biol. 8 2008 45
10. D.J. Bornhop, J.C. Latham, A. Kussrow, D.A. Markov, R.D. Jones, and H.S. Sorensen Free-solution, label-free molecular interactions studied by back-scattering interferometry Science 317 2007 1732 1736 (Pubitemid 47461834)
11. S. Borrmann, A.A. Adegnika, P.B. Matsiegui, S. Issifou, A. Schindler, D.P. Mawili-Mboumba, T. Baranek, J. Wiesner, H. Jomaa, and P.G. Kremsner Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children J. Infect. Dis. 189 2004 901 908 (Pubitemid 38328192)
12. S. Borrmann, S. Issifou, G. Esser, A.A. Adegnika, M. Ramharter, P.B. Matsiegui, S. Oyakhirome, D.P. Mawili-Mboumba, M.A. Missinou, J.F. Kun, H. Jomaa, and P.G. Kremsner Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria J. Infect. Dis. 190 2004 1534 1540 (Pubitemid 39411000)
13. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 48 2009 1 12
14. P.A. Brough, X. Barril, J. Borgognoni, P. Chene, N.G. Davies, B. Davis, M.J. Drysdale, B. Dymock, S.A. Eccles, C. Garcia-Echeverria, C. Fromont, and A. Hayes Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2, 3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone J. Med. Chem. 52 2009 4794 4809
15. A.C. Brown, and T. Parish Dxr is essential in Mycobacterium tuberculosis and fosmidomycin resistance is due to a lack of uptake BMC Microbiol. 8 2008 78
16. L. Buetow, A.C. Brown, T. Parish, and W.N. Hunter The structure of Mycobacteria 2C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery BMC Struct. Biol. 7 2007 68
17. S.K. Burley, A. Joachimiak, G.T. Montelione, and I.A. Wilson Contributions to the NIH-NIGMS Protein Structure Initiative from the PSI Production Centers Structure 16 2008 5 11
18. T.L. Campbell, and E.D. Brown Characterization of the depletion of 2-C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase in Escherichia coli and Bacillus subtilis J. Bacteriol. 184 2002 5609 5618
19. N. Campos, M. Rodriguez-Concepcion, S. Sauret-Gueto, F. Gallego, L.M. Lois, and A. Boronat Escherichia coli engineered to synthesize isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate: A novel system for the genetic analysis of the 2-C-methyl-d-erythritol 4-phosphate pathway for isoprenoid biosynthesis Biochem. J. 353 2001 59 67 (Pubitemid 32094600)
20. G.L. Card, L. Blasdel, B.P. England, C. Zhang, Y. Suzuki, S. Gillette, D. Fong, P.N. Ibrahim, D.R. Artis, G. Bollag, M.V. Milburn, and S.H. Kim A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design Nat. Biotechnol. 23 2005 201 207 (Pubitemid 40255330)
21. CCP4 The CCP4 suite: Programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
22. P.F. Chan, D.J. Holmes, and D.J. Payne Finding the gems using genomic discovery: Antibacterial drug discovery strategiesThe successes and the challenges Drug Discov. Today Ther. Strateg. 1 2004 519 527 (Pubitemid 40197600)
23. V.B. Chen, W.B. Arendall 3rd, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, and D.C. Richardson MolProbity: All-atom structure validation for macromolecular crystallography Acta Crystallogr. D Biol. Crystallogr. 66 2010 12 21
24. A. Ciulli, D.E. Scott, M. Ando, F. Reyes, S.A. Saldanha, K.L. Tuck, D.Y. Chirgadze, T.L. Blundell, and C. Abell Inhibition of Mycobacterium tuberculosis pantothenate synthetase by analogues of the reaction intermediate Chembiochem 9 2008 2606 2611
25. M. Congreve, R. Carr, C. Murray, and H. Jhoti A 'rule of three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877 (Pubitemid 37194496)
26. D.R. Davies, B. Mamat, O.T. Magnusson, J. Christensen, M.H. Haraldsson, R. Mishra, B. Pease, E. Hansen, J. Singh, D. Zembower, H. Kim, and A.S. Kiselyov Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography J. Med. Chem. 52 2009 4694 4715
27. I.W. Davis, A. Leaver-Fay, V.B. Chen, J.N. Block, G.J. Kapral, X. Wang, L.W. Murray, W.B. Arendall 3rd, J. Snoeyink, J.S. Richardson, and D.C. Richardson MolProbity: All-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 35 2007 W375 W383
28. W.L. DeLano Unraveling hot spots in binding interfaces: Progress and challenges Curr. Opin. Struct. Biol. 12 2002 14 20
29. W.L. DeLano The PyMOL Molecular Graphics System 2008 DeLano Scientific LLC Palo Alto, CA, USA
30. J. Deng, D.R. Davies, G. Wisedchaisri, M. Wu, W.G. Hol, and C. Mehlin An improved protocol for rapid freezing of protein samples for long-term storage Acta Crystallogr. D Biol. Crystallogr. 60 2004 203 204
31. B.H. Dessailly, R. Nair, L. Jaroszewski, J.E. Fajardo, A. Kouranov, D. Lee, A. Fiser, A. Godzik, B. Rost, and C. Orengo PSI-2: Structural genomics to cover protein domain family space Structure 17 2009 869 881
32. C.M. Dobson, T. Wai, D. Leclerc, H. Kadir, M. Narang, J.P. Lerner-Ellis, T.J. Hudson, D.S. Rosenblatt, and R.A. Gravel Identification of the gene responsible for the cblB complementation group of vitamin B12-dependent methylmalonic aciduria Hum. Mol. Genet. 11 2002 3361 3369 (Pubitemid 36054664)
33. C.D. Duarte, E.J. Barreiro, and C.A. Fraga Privileged structures: A useful concept for the rational design of new lead drug candidates Mini Rev. Med. Chem. 7 2007 1108 1119 (Pubitemid 350200217)
34. Edwards, T. E., Bullen, J., Abendroth, J., Sankaran, B., Staker, B. L., Van Voorhis, W. C., Myler, P. J., and Stewart, L. J. Structures of putative Mycobacterium arginine/ornithine transport system NTPases. Acta. Crystallogr. F (manuscript in preparation)
35. W. Eisenreich, A. Bacher, D. Arigoni, and F. Rohdich Biosynthesis of isoprenoids via the non-mevalonate pathway Cell. Mol. Life Sci. 61 2004 1401 1426 (Pubitemid 38858349)
36. P. Emsley, and K. Cowtan Coot: Model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60 2004 2126 2132 (Pubitemid 41742764)
37. H. Eoh, A.C. Brown, L. Buetow, W.N. Hunter, T. Parish, D. Kaur, P.J. Brennan, and D.C. Crick Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: Potential for drug development J. Bacteriol. 189 2007 8922 8927
38. D.A. Erlanson, R.S. McDowell, and T. O'Brien Fragment-based drug discovery J. Med. Chem. 47 2004 3463 3482 (Pubitemid 38822007)
39. P. Ertl, S. Jelfs, J. Muhlbacher, A. Schuffenhauer, and P. Selzer Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds J. Med. Chem. 49 2006 4568 4573 (Pubitemid 44162682)
40. J. Fejzo, C.A. Lepre, J.W. Peng, G.W. Bemis, Ajay, M.A. Murcko, and J.M. Moore The SHAPES strategy: An NMR-based approach for lead generation in drug discovery Chem. Biol. 6 1999 755 769 (Pubitemid 29485537)
41. B.G. Fox, C. Goulding, M.G. Malkowski, L. Stewart, and A. Deacon Structural genomics: From genes to structures with valuable materials and many questions in between Nat Methods 5 2008 129 132 (Pubitemid 351181737)
42. C. Freiberg, B. Wieland, F. Spaltmann, K. Ehlert, H. Brotz, and H. Labischinski Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria J. Mol. Microbiol. Biotechnol. 3 2001 483 489 (Pubitemid 32421672)
43. J.A. Gerlt A protein structure (or function ?) initiative Structure 15 2007 1353 1356 (Pubitemid 350054968)
44. P.J. Hajduk Fragment-based drug design: How big is too big? J. Med. Chem. 49 2006 6972 6976 (Pubitemid 44885985)
45. P.J. Hajduk Puzzling through fragment-based drug design Nat. Chem. Biol. 2 2006 658 659 (Pubitemid 44764204)
46. P.J. Hajduk, J.R. Huth, and C. Tse Predicting protein druggability Drug Discov. Today 10 2005 1675 1682 (Pubitemid 41817616)
47. M.M. Hann, A.R. Leach, and G. Harper Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 41 2001 856 864
48. M.J. Hartshorn, C.W. Murray, A. Cleasby, M. Frederickson, I.J. Tickle, and H. Jhoti Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 48 2005 403 413 (Pubitemid 40139783)
49. J.C. Hermann, R. Marti-Arbona, A.A. Fedorov, E. Fedorov, S.C. Almo, B.K. Shoichet, and F.M. Raushel Structure-based activity prediction for an enzyme of unknown function Nature 448 2007 775 779 (Pubitemid 47266333)
50. T. Hesterkamp, J. Barker, A. Davenport, and M. Whittaker Fragment based drug discovery using fluorescence correlation: Spectroscopy techniques: Challenges and solutions Curr. Top. Med. Chem. 7 2007 1582 1591 (Pubitemid 350138969)
51. A.L. Hopkins, C.R. Groom, and A. Alex Ligand efficiency: A useful metric for lead selection Drug Discov. Today 9 2004 430 431 (Pubitemid 38510559)
52. R.E. Hubbard, B. Davis, I. Chen, and M.J. Drysdale The SeeDs approach: Integrating fragments into drug discovery Curr. Top. Med. Chem. 7 2007 1568 1581 (Pubitemid 350131015)
53. W.N. Hunter The non-mevalonate pathway of isoprenoid precursor biosynthesis J. Biol. Chem. 282 2007 21573 21577 (Pubitemid 47195723)
54. M.A. Jacobs, A. Alwood, I. Thaipisuttikul, D. Spencer, E. Haugen, S. Ernst, O. Will, R. Kaul, C. Raymond, R. Levy, L. Chun-Rong, and D. Guenthner Comprehensive transposon mutant library of Pseudomonas aeruginosa Proc. Natl. Acad. Sci. USA 100 2003 14339 14344 (Pubitemid 37499238)
55. R.M. Jasmer, P. Nahid, and P.C. Hopewell Clinical practice. Latent tuberculosis infection N. Engl. J. Med. 347 2002 1860 1866 (Pubitemid 35417778)
56. H. Jomaa, J. Wiesner, S. Sanderbrand, B. Altincicek, C. Weidemeyer, M. Hintz, I. Turbachova, M. Eberl, J. Zeidler, H.K. Lichtenthaler, D. Soldati, and E. Beck Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs Science 285 1999 1573 1576 (Pubitemid 29420582)
57. W. Kabsch Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 26 1993 795 800
58. L.E. Kemp, M.S. Alphey, C.S. Bond, M.A. Ferguson, S. Hecht, A. Bacher, W. Eisenreich, F. Rohdich, and W.N. Hunter The identification of isoprenoids that bind in the intersubunit cavity of Escherichia coli 2C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase by complementary biophysical methods Acta Crystallogr. D Biol. Crystallogr. 61 2005 45 52 (Pubitemid 41615530)
59. G.M. Keseru, and G.M. Makara Hit discovery and hit-to-lead approaches Drug Discov. Today 11 2006 741 748 (Pubitemid 44038630)
60. N. Korotkova, and M.E. Lidstrom MeaB is a component of the methylmalonyl-CoA mutase complex required for protection of the enzyme from inactivation J. Biol. Chem. 279 2004 13652 13658 (Pubitemid 38468893)
61. N. Korotkova, L. Chistoserdova, V. Kuksa, and M.E. Lidstrom Glyoxylate regeneration pathway in the methylotroph Methylobacterium extorquens AM1 J. Bacteriol. 184 2002 1750 1758 (Pubitemid 34188227)
62. I.D. Kuntz, K. Chen, K.A. Sharp, and P.A. Kollman The maximal affinity of ligands Proc. Natl. Acad. Sci. USA 96 1999 9997 10002 (Pubitemid 29422500)
63. J.E. Ladbury, G. Klebe, and E. Freire Adding calorimetric data to decision making in lead discovery: A hot tip Nat. Rev. Drug Discov. 9 2010 23 27
64. B.M. Lange, T. Rujan, W. Martin, and R. Croteau Isoprenoid biosynthesis: The evolution of two ancient and distinct pathways across genomes Proc. Natl. Acad. Sci. USA 97 2000 13172 13177
65. C.A. Lepre, J.M. Moore, and J.W. Peng Theory and applications of NMR-based screening in pharmaceutical research Chem. Rev. 104 2004 3641 3676
66. A.H. Lipkus, Q. Yuan, K.A. Lucas, S.A. Funk, W.F. Bartelt 3rd, R.J. Schenck, and A.J. Trippe Structural diversity of organic chemistry. A scaffold analysis of the CAS Registry J. Org. Chem. 73 2008 4443 4451 (Pubitemid 351842458)
67. G.M. Makara On sampling of fragment space J. Med. Chem. 50 2007 3214 3221 (Pubitemid 47065970)
68. M. Mayer, and T.L. James NMR-based characterization of phenothiazines as a RNA binding scaffold J. Am. Chem. Soc. 126 2004 4453 4460 (Pubitemid 38453903)
69. M.A. Missinou, S. Borrmann, A. Schindler, S. Issifou, A.A. Adegnika, P.B. Matsiegui, R. Binder, B. Lell, J. Wiesner, T. Baranek, H. Jomaa, and P.G. Kremsner Fosmidomycin for malaria Lancet 360 2002 1941 1942 (Pubitemid 35472137)
70. I. Mochalkin, J.R. Miller, L. Narasimhan, V. Thanabal, P. Erdman, P.B. Cox, J.V. Prasad, S. Lightle, M.D. Huband, and C.K. Stover Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches ACS Chem. Biol. 4 2009 473 483
71. P.B. Moore Let's call the whole thing off: Some thoughts on the protein structure initiative Structure 15 2007 1350 1352 (Pubitemid 350051931)
72. C.P. Mpamhanga, D. Spinks, L.B. Tulloch, E.J. Shanks, D.A. Robinson, I.T. Collie, A.H. Fairlamb, P.G. Wyatt, J.A. Frearson, W.N. Hunter, I.H. Gilbert, and R. Brenk One scaffold, three binding modes: Novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening J. Med. Chem. 52 2009 4454 4465
73. G. Muller Medicinal chemistry of target family-directed masterkeys Drug Discov. Today 8 2003 681 691 (Pubitemid 36969999)
74. C.W. Murray, and T.L. Blundell Structural biology in fragment-based drug design Curr. Opin. Struct. Biol. 2010 20, 497507
75. P.J. Myler, R. Stacy, L. Stewart, B.L. Staker, W.C. Van Voorhis, G. Varani, and G.W. Buchko The Seattle Structural Genomics Center for Infectious Disease (SSGCID) Infect. Disord. Drug Targets 9 2009 493 506
76. R. Nair, J. Liu, T.T. Soong, T.B. Acton, J.K. Everett, A. Kouranov, A. Fiser, A. Godzik, L. Jaroszewski, C. Orengo, G.T. Montelione, and B. Rost Structural genomics is the largest contributor of novel structural leverage J. Struct. Funct. Genomics 10 2009 181 191
77. I. Navratilova, and A.L. Hopkins Fragment screening by surface plasmon resonance ACS Med. Chem. Lett. 1 2010 44 48
78. T. Neumann, H.D. Junker, K. Schmidt, and R. Sekul SPR-based fragment screening: Advantages and applications Curr. Top. Med. Chem. 7 2007 1630 1642 (Pubitemid 350131018)
79. S. Ni, K. McAteer, D.E. Bussiere, and M.A. Kennedy Crystallization and preliminary crystallographic analysis of an Enterococcus faecalis repressor protein, CylR2, involved in regulating cytolysin production through quorum-sensing Acta Crystallogr. D Biol. Crystallogr. 60 2004 1145 1148 (Pubitemid 41295463)
80. S. Ni, H. Robinson, G.C. Marsing, D.E. Bussiere, and M.A. Kennedy Structure of 2C-methyl-D-erythritol-2, 4-cyclodiphosphate synthase from Shewanella oneidensis at 1.6 A: Identification of farnesyl pyrophosphate trapped in a hydrophobic cavity Acta Crystallogr. D Biol. Crystallogr. 60 2004 1949 1957 (Pubitemid 41087524)
81. V.L. Nienaber, P.L. Richardson, V. Klighofer, J.J. Bouska, V.L. Giranda, and J. Greer Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 18 2000 1105 1108
82. J. Painter, and E.A. Merritt Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr. D Biol. Crystallogr. 62 2006 439 450
83. D.J. Payne, M.N. Gwynn, D.J. Holmes, and M. Rosenberg Genomic approaches to antibacterial discovery Methods Mol. Biol. 266 2004 231 259
84. D.J. Payne, M.N. Gwynn, D.J. Holmes, and D.L. Pompliano Drugs for bad bugs: Confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 6 2007 29 40 (Pubitemid 46020284)
85. M. Pellecchia Solution nuclear magnetic resonance spectroscopy techniques for probing intermolecular interactions Chem. Biol. 12 2005 961 971 (Pubitemid 41338806)
86. G.A. Petsko An idea whose time has gone Genome Biol. 8 2007 107
87. J.W. Pflugrath The finer things in X-ray diffraction data collection Acta Crystallogr. D Biol. Crystallogr. 55 1999 1718 1725 (Pubitemid 29504426)
88. J.F. Rakus, C. Kalyanaraman, A.A. Fedorov, E.V. Fedorov, F.P. Mills-Groninger, R. Toro, J. Bonanno, K. Bain, J.M. Sauder, S.K. Burley, S.C. Almo, and M.P. Jacobson Computation-facilitated assignment of the function in the enolase superfamily: A regiochemically distinct galactarate dehydratase from Oceanobacillus iheyensis Biochemistry 48 2009 11546 11558
89. D.C. Rees, M. Congreve, C.W. Murray, and R. Carr Fragment-based lead discovery Nat. Rev. Drug Discov. 3 2004 660 672 (Pubitemid 39173507)
90. A.B. Reitz, G.R. Smith, B.A. Tounge, and C.H. Reynolds Hit triage using efficiency indices after screening of compound libraries in drug discovery Curr. Top. Med. Chem. 9 2009 1718 1724
91. F. Rohdich, W. Eisenreich, J. Wungsintaweekul, S. Hecht, C.A. Schuhr, and A. Bacher Biosynthesis of terpenoids. 2C-Methyl-D-erythritol 2, 4-cyclodiphosphate synthase (IspF) from Plasmodium falciparum Eur. J. Biochem. 268 2001 3190 3197 (Pubitemid 32822992)
92. W.J. Sanders, V.L. Nienaber, C.G. Lerner, J.O. McCall, S.M. Merrick, S.J. Swanson, J.E. Harlan, V.S. Stoll, G.F. Stamper, S.F. Betz, K.R. Condroski, and R.P. Meadows Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization J. Med. Chem. 47 2004 1709 1718 (Pubitemid 38380914)
93. R.F. Service Structural biology. Protein structure initiative: Phase 3 or phase out Science 319 2008 1610 1613 (Pubitemid 351432481)
94. S.B. Shuker, P.J. Hajduk, R.P. Meadows, and S.W. Fesik Discovering high-affinity ligands for proteins: SAR by NMR Science 274 1996 1531 1534 (Pubitemid 26403929)
95. M.G. Siegel, and M. Vieth Drugs in other drugs: A new look at drugs as fragments Drug Discov. Today 12 2007 71 79 (Pubitemid 46014488)
96. E. Smith, and H.J. Morowitz Universality in intermediary metabolism Proc. Natl. Acad. Sci. USA 101 2004 13168 13173 (Pubitemid 39209637)
97. L. Song, C. Kalyanaraman, A.A. Fedorov, E.V. Fedorov, M.E. Glasner, S. Brown, H.J. Imker, P.C. Babbitt, S.C. Almo, M.P. Jacobson, and J.A. Gerlt Prediction and assignment of function for a divergent N-succinyl amino acid racemase Nat. Chem. Biol. 3 2007 486 491 (Pubitemid 47080369)
98. S. Steinbacher, J. Kaiser, J. Wungsintaweekul, S. Hecht, W. Eisenreich, S. Gerhardt, A. Bacher, and F. Rohdich Structure of 2C-methyl-d-erythritol-2, 4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids J. Mol. Biol. 316 2002 79 88 (Pubitemid 34729267)
99. E.E. Swayze, E.A. Jefferson, K.A. Sannes-Lowery, L.B. Blyn, L.M. Risen, S. Arakawa, S.A. Osgood, S.A. Hofstadler, and R.H. Griffey SAR by MS: A ligand based technique for drug lead discovery against structured RNA targets J. Med. Chem. 45 2002 3816 3819 (Pubitemid 35024285)
100. V. Ulaganathan, M.F. Agacan, L. Buetow, L.B. Tulloch, and W.N. Hunter Structure of Staphylococcus aureus1, 4-dihydroxy-2-naphthoyl-CoA synthase (MenB) in complex with acetoacetyl-CoA Acta Crystallogr. F Struct. Biol. Cryst. Commun. 63 2007 908 913 (Pubitemid 350134956)
101. W.C. Van Voorhis, W.G. Hol, P.J. Myler, and L.J. Stewart The role of medical structural genomics in discovering new drugs for infectious diseases PLoS Comput. Biol. 5 2009 e1000530
102. T.J. Waybright, J.R. Britt, and T.G. McCloud Overcoming problems of compound storage in DMSO: Solvent and process alternatives J. Biomol. Screen. 14 2009 708 715
103. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009 (Pubitemid 350273630)
104. J. Wiesner, D. Henschker, D.B. Hutchinson, E. Beck, and H. Jomaa In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin Antimicrob. Agents Chemother. 46 2002 2889 2894
105. J. Wiesner, S. Borrmann, and H. Jomaa Fosmidomycin for the treatment of malaria Parasitol. Res. 90 Suppl 2 2003 S71 S76
106. J. Yuvaniyama, P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, W. Sirawaraporn, P. Taylor, M.D. Walkinshaw, and Y. Yuthavong Insights into antifolate resistance from malarial DHFR-TS structures Nat. Struct. Biol. 10 2003 357 365 (Pubitemid 36523270)
107. E. Zartler, and M. Shapiro Fragment-based drug discovery: A practical approach 2008 John Wiley & Sons Hoboken, N.J